Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. METHODS: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed. RESULTS: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03). CONCLUSIONS: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials have shown that targeted inhibition of this inflammatory pathway, as measured by changes in CRP concentrations, can reduce the rate of cardiovascular events.5, 6, 7”
From Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was also not an isolated finding as a similar reduction of CVD risk linked to reduction of inflammation was reported in the COLCOT trial when participants were given low‐dose colchicine (a standard anti‐inflammatory drug) (Tardif et al., 2019).”
From Treatment of periodontitis and C ‐reactive protein: A systematic review and meta‐analysis of randomized clinical trials (2023) · cites this paper as Tardif et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“However, when appraised together, the evidence supports apolipoprotein B as being necessary for lipid-mediated atherogenesis by LDL-C to occur. 57,58 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [58]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
Ravelli, R. B. G., Gigant, B., Curmi, P. A., Jourdain, I., Lachkar, S., Sobel, A., & Knossow, M. (2004) · Nature · doi:10.1038/nature02393 · Cited by 1,630
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Self-citationLow-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,054
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.542738 · Cited by 614
Cited by
Items 301–400 of 1,006
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman, R., Merdler, I., Case, B. C., Waksman, O., & Porto, I. (2023) · EuroIntervention · doi:10.4244/eij-d-23-00606 · Cited by 94
“The primary composite endpoint was defined as the time to first event of one of the following: cardiovascular death, cardiac arrest, MI, stroke, or urgent hospitalisation for angina requiring coronary revascularisation 80 .”
Inflammation as a Treatment Target after Acute Myocardial Infarction
Newby, L. K. (2019) · New England Journal of Medicine · doi:10.1056/nejme1914378 · Cited by 78
Luthra, S., Orlandi, M., Hussain, S. B., Leira, Y., Botelho, J., Machado, V., Mendes, J. J., Marletta, D., Harden, S., & D'Aiuto, F. (2023) · Journal of Clinical Periodontology · doi:10.1111/jcpe.13709 · Cited by 74
“This was also not an isolated finding as a similar reduction of CVD risk linked to reduction of inflammation was reported in the COLCOT trial when participants were given low-dose colchicine (a standard anti-inflammatory drug) (Tardif et al., 2019).”
Hiram, R., Xiong, F., Naud, P., Xiao, J., Sirois, M. G., Tanguay, J., Tardif, J., & Nattel, S. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa186 · Cited by 85
“Colchicine, a fairly innocuous and widely used agent with antiinflammatory properties, has also recently been demonstrated in a large-scale randomized study to prevent myocardial infarction and stroke after an index event.(40) The field of inflammation-modulating therapeutics for cardiovascular disease appears to be b…”
BackgroundSelf-citationPluijmert, N. J., Atsma, D. E., & Quax, P. H. A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.647785 · Cited by 86
Kerola, A. M., Rollefstad, S., & Semb, A. G. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.44 · Cited by 84
“1016/S01406736(94)90566-5; PMID: 7968073.”
oxLDL-Induced Trained Immunity Is Dependent on Mitochondrial Metabolic Reprogramming
Groh, L. A., Ferreira, A. V., Helder, L. S., van der Heijden, C. D. C. C., Novakovic, B., van de Westerlo, E., Matzaraki, V., Moorlag, S. J. C. F. M., de Bree, L. C. J., Koeken, V. A. C. M., et al. (2021) · Immunometabolism · doi:10.20900/immunometab20210025 · Cited by 88
“The primary pathophysiological process giving rise to CVD is atherosclerosis, which is characterized by the build-up of lipid-laden plaques within arteries.”
BackgroundInfluentialDoi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.05.010 · Cited by 72
Scheller, M., Ludwig, A. K., Göllner, S., Rohde, C., Krämer, S., Stäble, S., Janssen, M., Müller, J.-A., He, L., Bäumer, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00213-9 · Cited by 73
A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges
Hossen, M. S., Barek, M. A., Jahan, N., & Islam, M. S. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00485-9 · Cited by 77
“A study on 4745 patients was reported that colchicine significantly decreased cardiovascular risk and pneumonia [79].”
BackgroundMethodColchicine exerts anti‐atherosclerotic and ‑plaque‐stabilizing effects targeting foam cell formation
Schwarz, N., Fernando, S., Chen, Y., Salagaras, T., Rao, S. R., Liyanage, S., Williamson, A. E., Toledo‐Flores, D., Dimasi, C. G., Sargeant, T. J., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202201469r · Cited by 82
Colchicine: the good, the bad, the ugly and how to minimize the risks
Stamp, L. K., Horsley, C., Karu, L. T., Dalbeth, N., & Barclay, M. L. (2023) · Rheumatology · doi:10.1093/rheumatology/kead625 · Cited by 85
Vaccination Strategies and Immune Modulation of Atherosclerosis
Nilsson, J. Å., & Hansson, G. K. (2020) · Circulation Research · doi:10.1161/circresaha.120.315942 · Cited by 76
Emerging roles of neutrophil-borne S100A8/A9 in cardiovascular inflammation
Sreejit, G., Abdel Latif, A., Murphy, A. J., & Nagareddy, P. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105212 · Cited by 72
“Another trial, The Colchicine Cardiovascular Outcomes Trial (COLCOT) that investigated the efficacy of colchicine to reduce the risk of cardiovascular events after MI found similar data (11).”
BackgroundTryptophan: From Diet to Cardiovascular Diseases
Melhem, N. J., & Taleb, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189904 · Cited by 80
“Recent studies showed that targeting inflammation may represent a promising therapeutic approach to reduce acute CV events [8,9].”
BackgroundLi, J., Lin, J., Pan, Y., Wang, M., Meng, X., Li, H., Wang, Y., Zhao, X., 秦海强, Liu, L., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02467-1 · Cited by 77
Zhao, Z., Zhang, X., Sun, T., Huang, X., Ma, M., Yang, S., & Zhou, Y. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14100 · Cited by 90
“53,54 We look forward to more evidence of the benefits of targeted interventions against systemic inflammation in patients with CAD and the advent of new anti-inflammation drugs.”
BackgroundВалерьевич, А. О., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Konstantinova, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6306 · Cited by 100
Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction
Rout, A., Tantry, U. S., Novaković, M., Sukhi, A., & Gurbel, P. A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787987 · Cited by 76
Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives
Sagris, Μ., Theofilis, P., Antonopoulos, A. S., Tsioufis, C. P., Oikonomou, E. K., Antoniades, C. A., Crea, F., Kaski, J. C., & Tousoulis, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126607 · Cited by 75
“Atherosclerotic animal trials in LDL receptor-deficient mice recorded decreased levels of pro-inflammatory cytokines, eventually leading to diminished NF-κB activation, and improved atherosclerotic plaque stabilization following acetylsalicylic acid therapy [79].”
BackgroundColchicine Impacts Leukocyte Trafficking in Atherosclerosis and Reduces Vascular Inflammation
Meyer-Lindemann, U., Mauersberger, C., Schmidt, A.-C., Moggio, A., Hinterdobler, J., Li, X., Khangholi, D., Hettwer, J., Gräßer, C., Dutsch, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898690 · Cited by 75
“This concept was further reinforced by two recent trials using the antiinflammatory drug colchicine (7, 8): In the Colchicine Cardiovascular Outcomes Trial (COLCOT), colchicine led to a significantly lower risk of ischemic cardiovascular events in patients with prior MI (7) while in the Low-Dose Colchicine (LoDoCo) 2…”
Inflammasome Signaling, Thromboinflammation, and Venous Thromboembolism
Potere, N., Abbate, A., Kanthi, Y. M., Carrier, M., Toldo, S. A., Porreca, E., & Nisio, M. D. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.03.017 · Cited by 93
“In COLCOT (Colchicine Cardiovascular Outcomes Trial), lowdose colchicine reduced coronary and cerebral thrombotic events in patients with recent acute myocardial infarction.(112) IL-1 inhibitors are available for clinical use.”
BackgroundMechanisms of fibrous cap formation in atherosclerosis
Alonso-Herranz, L., Albarrán-Juárez, J., & Bentzon, J. F. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1254114 · Cited by 91
“Anti-inflammatory therapies, such as IL1B antagonism and colchicine, reduce the incidence of clinical events in patients with advanced atherosclerosis (52, 53), but whether this is achieved partly by increasing cap thickness is also unknown.”
BackgroundRevisiting regulatory T cells as modulators of innate immune response and inflammatory diseases
Ou, Q., Power, R., & Griffin, M. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1287465 · Cited by 81
Dysregulated cellular metabolism in atherosclerosis: mediators and therapeutic opportunities
Stroope, C., Nettersheim, F. S., Coon, B. G., Finney, A. C., Schwartz, M. A., Ley, K. F., Rom, O., & Yurdagul, A. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01015-w · Cited by 77
Discovering Inflammation in Atherosclerosis: Insights from Pathogenic Pathways to Clinical Practice
Madaudo, C., Coppola, G., Parlati, A. L. M., & Corrado, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116016 · Cited by 85
“In COLCOT, at a median follow-up of 22.6 months, Colchicine demonstrated a 23% reduction in primary endpoint (CVD, resuscitated cardiac arrest, MI, stroke, urgent hospitalization for angina leading to coronary revascularization) [134].”
BackgroundMethodInfluentialMcCabe, J. J., O’Reilly, É. J., Coveney, S. A., Collins, R., Healy, L., McManus, J., Mulcahy, R., Moynihan, B., Cassidy, T., Hsu, F., et al. (2021) · European Stroke Journal · doi:10.1177/2396987320984003 · Cited by 78
Ries, W., Torzewski, J., Heigl, F., Pfluecke, C., Kelle, S., Darius, H., Ince, H., Mitzner, S. R., Nordbeck, P., Butter, C., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.591714 · Cited by 76
“Both IL-1ß-blockade and colchicine have been shown to reduce mortality by lowering inflammation and especially CRP levels (32, 33).”
BackgroundBurger, P. M., Pradhan, A. D., Dorresteijn, J. A. N., Koudstaal, S., Teraa, M., de Borst, G. J., van der Meer, M. G., Mosterd, A., Ridker, P. M., & Visseren, F. L. J. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.03.025 · Cited by 73
Interleukin-6 and Cardiovascular Events in Healthy Adults
Khan, M. S., Talha, K. M., Maqsood, M. H., Rymer, J. A., Borlaug, B. A., Docherty, K. F., Pandey, A., Kahles, F., Čikeš, M., Lam, C. S. P., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101063 · Cited by 93
Georgakis, M. K., Malik, R., Li, X., Gill, D., Levin, M. G., Vy, H. M. T., Judy, R., Ritchie, M. D., Verma, S. S., Nadkarni, G. N., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052604 · Cited by 73
Mary, Y. S., Mary, Y. S., Armaković, S., Armaković, S. J., Yadav, R., Çeli̇k, İ., Mane, P., & Chakraborty, B. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.116192 · Cited by 68
Kraler, S., Libby, P., Evans, P. C., Akhmedov, A., Schmiady, M. O., Reinehr, M., Camici, G. G., & Lüscher, T. F. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.121.316256 · Cited by 65
Anti‐inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy
Li, Y., Zhang, Y., Lu, J., Yin, Y., Xie, J., & Xu, B. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16798 · Cited by 77
Silvis, M. J. M., Fiolet, A. T. L., Opstal, T. S. J., Dekker, M., Suquilanda, D., Živkovic, M., Duyvendak, M., The, S. H. K., Timmers, L., Bax, W. A., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.08.005 · Cited by 74
Wang, P., Yuan, D., Zhang, C., Zhu, P., Jia, S., Song, Y., Tang, X., Xu, J., Li, T., Zeng, G., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01477-w · Cited by 73
“The results focusing on patients with recent MI in this RCT have confirmed the safety and efficacy of colchicine [33].”
BackgroundResearch Progress on the Role of Pyroptosis in Myocardial Ischemia-Reperfusion Injury
Yang, L., Zhang, J., Zhang, D., Yu, P., Zhang, J., & Yu, S. (2022) · Cells · doi:10.3390/cells11203271 · Cited by 77
“5 mg per day led to a significantly lower risk of ischemic cardiovascular events compared to placebo and reduced the costs of standard care after myocardial infarction [85,86].”
BackgroundLipid-lowering in diabetes: An update
Chait, A., Eckel, R. H., Vrablík, M., & Zambon, A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117313 · Cited by 81
Clonal hematopoiesis and atherosclerosis
Oren, O., Small, A. M., & Libby, P. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180066 · Cited by 82
“Randomized controlled trials of the antiinflammatory agent colchicine in patients with history of myocardial infarction demonstrated a significantly lower risk of ischemic cardiovascular events compared with placebo (45, 46).”
BackgroundFitzGerald, J. D. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03951 · Cited by 78
Inflammatory Mediators of Platelet Activation: Focus on Atherosclerosis and COVID-19
Theofilis, P., Sagris, Μ., Antonopoulos, A. S., Oikonomou, E. K., Tsioufis, C. P., & Tousoulis, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011170 · Cited by 76
“Colchicine has also demonstrated considerable efficacy in patients with stable coronary artery disease [152] or after myocardial infarction [80], by decreasing the risk of future cardiovascular events when administered in a low dose.”
BackgroundFunctional role of skeletal muscle-derived interleukin-6 and its effects on lipid metabolism
Lin, W., Song, H., Shen, J., Wang, J., Yang, Y., Yang, Y., Cao, J., Xue, L., Zhao, F., Xiao, T., et al. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1110926 · Cited by 81
“Gradually, inflammation contributes to atherosclerosis pathogenesis (Libby and Hansson, 2019; O’Keefe, 2019; Tardif et al., 2019).”
BackgroundPuri, R., Bansal, M., Mehta, V., Duell, P. B., Wong, N. D., Iyengar, S., Kalra, D. K., Nair, D. R., Nanda, N. C., Narula, J., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.006 · Cited by 83
Fiolet, A. T. L., Poorthuis, M. H. F., Opstal, T. S. J., Amarenco, P., Boczar, K. E., Buysschaert, I., Budgeon, C. A., Chan, N., Cornel, J. H., Jolly, S. S., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102835 · Cited by 72
Self-citationNLRP3 inflammasome in cardiovascular diseases: an update
Mo, B., Ding, Y., & Ji, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1550226 · Cited by 85
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“These include PCSK9 inhibitors (e.g., evolocumab [65]) and anti-inflammatory agents, such as colchicine [66].”
BackgroundSandhu, T., Tieng, A. T., Chilimuri, S. S., & Franchin, G. (2020) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2020/8865954 · Cited by 69
Härdtner, C., Kornemann, J., Krebs, K., Ehlert, C. A., Jander, A., Zou, J., Starz, C., Rauterberg, S., Sharipova, D., Dufner, B., et al. (2020) · Basic Research in Cardiology · doi:10.1007/s00395-020-00838-4 · Cited by 66
Xie, S., Galimberti, F., Olmastroni, E., Lüscher, T. F., Carugo, S., Catapano, A. L., Casula, M., META-LIPID Group, Catapano, A. L., Casula, M., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae034 · Cited by 74
Self-citationThe CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease
Bosmans, L. A., Bosch, L., Kusters, P. J. H., Lutgens, E., & Seijkens, T. T. P. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09994-3 · Cited by 67
Interleukin-1β and Risk of Premature Death in Patients With Myocardial Infarction
Silvain, J., Kernéis, M., Zeitouni, M., Lattuca, B., Galier, S., Brugier, D., Mertens, E., Procopi, N., Suc, G., Salloum, T., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.026 · Cited by 73
Targeting Inflammation to Reduce Residual Cardiovascular Risk
Ajala, O. N., & Everett, B. M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00883-3 · Cited by 65
Regulatory T Cell Stability and Plasticity in Atherosclerosis
Ali, A. J., Makings, J., & Ley, K. (2020) · Cells · doi:10.3390/cells9122665 · Cited by 65
“Two recent clinical trials (CANTOS and COLCOT) show that anti-inflammatory therapies can have beneficial effects for outcomes of atherosclerosis, including myocardial infarction, cardiovascular death, and stroke [2,3].”
BackgroundOprescu, N., Micheu, M. M., Scafa‐Udriște, A., Popa‐Fotea, N., & Dorobanţu, M. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1916070 · Cited by 69
“Our results sustain and enhance the inflammatory hypothesis of atherothrombosis, in line with trials such as CANTOS [13], COLCOT [22], LoDoCo 1 [23] and 2 [24].”
ResultSun, X., Duan, J., Gong, C., Feng, Y., Hu, J., Gu, R., & Xu, B. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025266 · Cited by 70
“8 Recent clinical trials have demonstrated that low-dose colchicine has potential benefits in a range of coronary diseases because of its anti-inflammatory effect.”
Intracranial Atherosclerosis Treatment
Flusty, B., de Havenon, A., Prabhakaran, S., Liebeskind, D. S., & Yaghi, S. R. (2020) · Stroke · doi:10.1161/strokeaha.119.028528 · Cited by 67
“70]).(17) Future studies are needed to examine anti-inflammatory therapies specifically in treatment of symptomatic ICAD.”
BackgroundDemidowich, A. P., Levine, J. A., Apps, R., Cheung, F., Chen, J., Fantoni, G., Zhou, H., Shi, R., Subramanian, P., Tsang, J., et al. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0598-3 · Cited by 69
Kelly, P. J., Weimar, C., Lemmens, R., Murphy, S., Purroy, F. F., Arsovska, A. A., Bornstein, N. M., Członkowska, A., Fischer, U., Fonseca, A. C., et al. (2021) · European Stroke Journal · doi:10.1177/2396987320972566 · Cited by 72
“In the LoDoCo and COLCOT trials, low-dose colchicine reduced recurrent events in coronary patients already treated with background modern preventive therapy.(14,15) A meta-analysis of stroke outcomes in coronary trials reported a 69% pooled risk reduction for stroke (although limited by few stroke outcomes).”
BackgroundAssociation of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio
Adamstein, N. H., Cornel, J. H., Davidson, M. H., Libby, P., Remigis, A. D., Jensen, C., Ekström, K., & Ridker, P. M. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4277 · Cited by 64
Colchicine for secondary prevention of vascular events: a meta-analysis of trials
d’Entremont, M.-A., Poorthuis, M. H. F., Fiolet, A. T. L., Amarenco, P., Boczar, K. E., Buysschaert, I., Chan, N., Cornel, J. H., Jannink, J., Jansen, S. J., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf210 · Cited by 75
Cardiovascular and Metabolic Protection by Vitamin E: A Matter of Treatment Strategy?
Ziegler, M., Wallert, M., Lorkowski, S., & Peter, K. (2020) · Antioxidants · doi:10.3390/antiox9100935 · Cited by 70
Lim, W., Corden, B., Ng, B., Vanezis, K., D’Agostino, G. A., Widjaja, A. A., Song, W., Xie, C., Su, L., Kwek, X.-Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74944-7 · Cited by 65
Lipoproteins in chronic kidney disease: from bench to bedside
Speer, T., Ridker, P. M., von Eckardstein, A., Schunk, S. J., & Fliser, D. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1050 · Cited by 69
Colchicine and SARS-CoV-2: Management of the hyperinflammatory state
Vitiello, A., & Ferrara, F. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106322 · Cited by 65
Jarr, K.-U., Ye, J., Kojima, Y., Ye, Z., Gao, H., Schmid, S., Luo, L., Baylis, R. A., Lotfi, M., Lopez, N. G., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00023-x · Cited by 70
The Roles of Neutrophils Linking Periodontitis and Atherosclerotic Cardiovascular Diseases
Irwandi, R. A., Chiesa, S. T., Hajishengallis, G., Papayannopoulos, V., Deanfield, J. E., & D’Aiuto, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915081 · Cited by 76
“Unfortunately, patients in the colchicine group showed higher incidents of pneumonia and non-cardiovascular-caused death than those in the placebo group (127, 128).”
BackgroundMolecular and cellular mechanisms of inflammation in atherosclerosis
Popa‐Fotea, N., Ferdoschi, C., & Micheu, M.-M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1200341 · Cited by 74
“Colchicine is an antiinflammatory drug inhibiting cytoskeletal microtubule formation used in pericarditis and acute gout that also proved to reduce a composite end-point of death from cardiovascular causes, spontaneous MI, ischemic stroke or ischemia-driven coronary revascularization in both chronic coronary artery di…”
Atherosclerosis and inflammation. New therapeutic approaches
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.04.020 · Cited by 82
Combating Inflammation in Cardiovascular Disease
Sethwala, A., Goh, I. Y., & Amerena, J. V. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.09.003 · Cited by 69
Colchicine Inhibits NETs and Alleviates Cardiac Remodeling after Acute Myocardial Infarction
Li, Y., Chen, S., Yang, Y., Zhang, Z.-H., Zhou, W., Huang, Y., Huang, Z., He, J., Chen, T., Wang, J., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07326-y · Cited by 67
“Clinical studies revealed that early treatment of colchicine reduced the risk of ischemic cardiovascular events in patients suffering with recent myocardial infarction [8, 9].”
Bay, B., Tanner, R., Gao, M., Oliva, A., Sartori, S., Vogel, B., Gitto, M., Smith, K. F., Muro, F. M. D., Hooda, A., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf196 · Cited by 82
Kofler, T., Kurmann, R., Lehnick, D., Cioffi, G. M., Chandran, S., Attinger‐Toller, A., Toggweiler, S., Kobza, R., Moccetti, F., Cuculi, F., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021198 · Cited by 74
Colchicine for acute and chronic coronary syndromes
Imazio, M., Andreis, A., Brucato, A. L., Adler, Y., & Ferrari, G. M. D. (2020) · Heart · doi:10.1136/heartjnl-2020-317108 · Cited by 73
Poels, K., Neppelenbroek, S. I. M., Kersten, M. J., Antoni, M. L., Lutgens, E., & Seijkens, T. T. P. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002916 · Cited by 71
Targeting inflammation in hypertension
Deußen, A., & Kopaliani, I. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000862 · Cited by 70
“Several clinical anti-inflammatory trials such as CANTOS[7],CIRT[8]andLoDoCo2[9,10]gavepromising but still inconclusive findings.”
BackgroundCate, H. T., Guzik, T. J., Eikelboom, J. W., & Spronk, H. M. H. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa263 · Cited by 68
Joshi, A., Schmidt, L. E., Burnap, S. A., Lu, R., Chan, M. V., Armstrong, P. C. J., Baig, F., Gutmann, C., Willeit, P., Santer, P., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.317113 · Cited by 60
Inflammation and the Link to Vascular Brain Health: Timing Is Brain
Mun, K. T., & Hinman, J. D. (2022) · Stroke · doi:10.1161/strokeaha.121.032613 · Cited by 65
Immunothrombosis: Molecular Aspects and New Therapeutic Perspectives
Marcos‐Jubilar, M., Lecumberri, R., & Páramo, J. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041399 · Cited by 73
“Inflammasome inhibitors (NLRP3) MCC950 [71], colchicine [73,74].”
BackgroundRoubille, F., Bouabdallaoui, N., Kouz, S., Waters, D. D., Díaz, R., Maggioni, A. P., Pinto, F. J., Grégoire, J. C., Gamra, H., Kiwan, G. S., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1825 · Cited by 60
Self-citationBreaking tolerance: the autoimmune aspect of atherosclerosis
Khan, A. S., Roy, P., & Ley, K. F. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01010-y · Cited by 69
Extracellular vesicle signalling in atherosclerosis
Charla, E., Mercer, J. R., Maffia, P., & Nicklin, S. A. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109751 · Cited by 68
Misra, D. P., Gasparyan, A. Y., & Zimba, O. (2020) · Rheumatology International · doi:10.1007/s00296-020-04694-2 · Cited by 66
Xia, M., Yang, X., & Qian, C. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.10.043 · Cited by 68
Obesity and Cardiovascular Disease: The Emerging Role of Inflammation
Khafagy, R., & Dash, S. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.768119 · Cited by 60
“It concluded that low-dose colchicine resulted in a significantly lower risk of cardiovascular events compared to placebo post-myocardial infarction (79).”
BackgroundMethodInfluentialColchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome
Opstal, T. S. J., Fiolet, A. T. L., van Broekhoven, A., Mosterd, A., Eikelboom, J. W., Nidorf, S. M., Thompson, P. L., Duyvendak, M., van Eck, J. W. M., van Beek, E. A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.037 · Cited by 66
Immune Mechanisms of Plaque Instability
Gerhardt, T., Haghikia, A., Stapmanns, P., & Leistner, D. M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.797046 · Cited by 77
Role of Inflammation in Cardiac Remodeling After Acute Myocardial Infarction
Fonseca, F. A. H., & Izar, M. C. D. O. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.927163 · Cited by 68
Yu, L., Xu, L., Chu, H., Peng, J., Sacharidou, A., Hsieh, H.-H., Weinstock, A., Khan, S., Ma, L., Durán, J. G. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39586-z · Cited by 66
Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease
Zheng, W. C., Chan, W., Dart, A., & Shaw, J. A. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad074 · Cited by 59
Andreis, A., Imazio, M., Piroli, F., Avondo, S., Casula, M., Paneva, E., & Ferrari, G. M. D. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab045 · Cited by 69
Wang, L., Peng, Y.-F., Song, L., Xia, D., Li, C., Li, Z., Li, Q., Yu, A., Lu, C., & Wang, Y. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07239-2 · Cited by 60
“Tardif found that low-dose colchicine led to a significantly lower risk of ischemic cardiovascular events for patients with a recent myocardial infarction [6].”
BackgroundRevisiting secondary prevention in coronary heart disease
Sigamani, A., & Gupta, R. (2022) · Indian Heart Journal · doi:10.1016/j.ihj.2022.11.011 · Cited by 87
Gerhardt, T., Seppelt, C., Abdelwahed, Y. S., Meteva, D., Wolfram, C., Stapmanns, P., Erbay, A., Zanders, L., Nelles, G., Musfeld, J., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad334 · Cited by 68
“15,16 OPTIcal-COherence Tomography in Acute Coronary Syndrome now for the first time combined vascular risk assessment through IL-6 and IL-1 β with optical plaque phenotyping by OCT and secondary outcome analysis, demonstrating that the RIR is higher after RFC-ACS than after IFC-ACS and that worse…”
MethodLuo, J., Qin, X., Zhang, X., Zhang, Y., Fang, Y., Shi, W., Liu, B., Wei, Y., & the NOAFCAMI-SH Registry Investigators (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02129-x · Cited by 61
“Nevertheless, previous research exploring the clinical usefulness of anti-inflammatory therapies in AMI has obtained controversial results [7], some studies support the utility of anti-inflammatory drugs [8, 9], while others are against it [10, 11].”
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Barkas, F., Şener, Y. Z., Golforoush, P. A., Kheirkhah, A., Rodríguez‐Sánchez, E., Novák, J., Apellániz-Ruiz, M., Akyea, R. K., Bianconi, V., Ceasovschih, A., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117579 · Cited by 65
Shamsuzzaman, S., Deaton, R. A., Salamon, A., Doviak, H., Serbulea, V., Milosek, V. M., Evans, M. A., Karnewar, S., Saibaba, S., Alencar, G. F., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067931 · Cited by 64
Targeting Inflammation After Acute Myocardial Infarction
Imbesi, A., Greco, A., Spagnolo, M., Laudani, C., Raffo, C., Finocchiaro, S., Mazzone, P. M., Landolina, D., Mauro, M. S., Cutore, L., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.064 · Cited by 83
Cardiovascular events and the role of accelerated atherosclerosis in systemic vasculitis
Clifford, A. H., & Tervaert, J. W. C. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.032 · Cited by 58
Cole, J., Htun, N., Lew, R., Freilich, M. I., Quinn, S. J., & Layland, J. J. (2021) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.120.009992 · Cited by 61
Metadata
- Authors
- Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M.-A., Dubé, M.-P., Rhainds, D., Provencher, M., Blondeau, L., Orfanos, A., L’Allier, P. L., Guertin, M.-C., & Roubille, F.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- From the Montreal Heart Institute (J.-C.T., R.I., J.C.G., M.-A.L., M.-P.D., D.R., P.L.L.) and the Montreal Health Innovations Coordinating Center (M.P., L.B., A.O., M.-C.G.), Montreal, Centre Hospitalier Régional de Lanaudière, Joliette (S.K.), and Institut de Cardiologie et Pneumologie de Québec, Quebec City (O.F.B.) — all in Canada; San Francisco General Hospital, San Francisco (D.D.W.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); Associazione Nazionale Medici Cardiologi...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-12-26
- Volume
- 381
- Issue
- 26
- Pages
- 2497-2505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2986700515
- Cited by
- 3,159
- References
- 20
- Citations by year
- 2026: 505 · 2025: 519 · 2024: 445 · 2023: 415 · 2022: 414 · 2021: 485 · 2020: 361 · 2019: 10
- FWCI
- 230.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Funders
- Government of Quebec
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- colchicine, myocardial infarction, anti-inflammatory therapy, inflammation in atherosclerosis, cardiovascular mortality, major adverse cardiovascular events, stroke, angina pectoris, diarrhea, pneumonia, drug safety, low-dose colchicine, secondary prevention, coronary revascularization, cardiac arrest, myocardial infarction recurrence, cardiovascular risk reduction, cost-effectiveness, quality of life
- MeSH terms
- Aged, Angina Pectoris, Anti-Inflammatory Agents, C-Reactive Protein, Cardiovascular Diseases, Colchicine, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Recurrence, Biomarkers, Incidence, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate, Intention to Treat Analysis, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

